<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paget disease of the breast (PDB)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paget disease of the breast (PDB)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paget disease of the breast (PDB)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael S Sabel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald L Weaver, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lori J Pierce, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In 1874, Sir James Paget described 15 women with chronic nipple ulceration who all went on to develop cancer of the involved breast within two years [<a href="#rid1">1</a>]. The ulceration was described as an eczema-like eruption on the nipple and areola with a copious clear yellowish exudate. Ultimately, this would become known as Paget disease of the breast (PDB) or mammary Paget disease. While Paget believed that the nipple changes were themselves benign, it was subsequently discovered that the characteristic cells within the epidermis of the nipple (Paget cells) were in fact malignant [<a href="#rid2">2</a>].</p><p>This topic review will discuss the clinical presentation, pathogenesis, pathology, diagnosis, and management of mammary Paget disease.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PDB is much less common than other presentations of breast cancer, accounting for only 1 to 3 percent of new cases of female breast cancer that are diagnosed annually in the United States [<a href="#rid3">3-7</a>]. PDB can occur in men; however, this is an extremely rare finding. Although cases have been described in patients ranging in age from 26 to 88, the peak incidence is between 50 and 60 [<a href="#rid8">8-11</a>].</p><p>Histologic (subclinical) evidence of PDB may be more frequent. In a series of 3000 consecutive mastectomy specimens, the incidence of clinical Paget disease was 0.7 percent, but histologic evidence of the disease was present in 4.9 percent of the mastectomies [<a href="#rid12">12</a>].</p><p>At least some epidemiologic data suggest that the incidence of PDB is decreasing over time [<a href="#rid13">13</a>]. In a report of 1738 cases of PDB reported to the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of PDB decreased by 45 percent between 1988 and 2002, while the overall incidence of breast cancer increased over this same time period.</p><p>Although PDB is a less common presentation of breast cancer than a palpable mass or mammographic abnormality, it is an important consideration in the differential diagnosis of a chronic persistent abnormality of the nipple.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The hallmark of PDB is a scaly, raw, vesicular, or ulcerated lesion that begins on the nipple and then spreads to the areola (<a class="graphic graphic_picture graphicRef60575" href="/z/d/graphic/60575.html" rel="external">picture 1</a>). Occasionally, a bloody discharge is present. PDB is usually unilateral, although bilateral cases have been described [<a href="#rid14">14</a>]. Nipple retraction is also a rare finding but may occur with more advanced disease.</p><p>Pain, burning, and/or pruritus are commonly associated with PDB and may be present before the development of clinically apparent disease. Thus, any patient complaining of these symptoms but without an obvious lesion should be followed closely if the symptoms persist. Despite the superficial nature of the findings, the median duration of signs and symptoms prior to histologic diagnosis is between six and eight months [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">DIAGNOSTIC WORKUP</span><span class="headingEndMark"> — </span>The diagnostic workup of suspected PDB focuses on both establishing the diagnosis and identifying an underlying breast cancer. An underlying breast cancer (in situ or invasive) is present in 85 to 88 percent of cases, although often without an associated breast mass or mammographic abnormality [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A palpable breast mass is present in 50 percent of cases of PDB; the mass is often located more than 2 cm from the nipple-areolar complex [<a href="#rid3">3,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 20 percent of cases, a mammographic abnormality is present without a palpable mass [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 12 to 15 percent of cases are not associated with a palpable mass, mammographic abnormality, or parenchymal breast cancer [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 25 percent of cases, there is neither an underlying mass nor a mammographic abnormality, but an occult ductal carcinoma in situ (DCIS) is present.</p><p></p><p>Patients with either a palpable mass or a mammographic abnormality are more likely to have an underlying invasive cancer, while DCIS is found more often in the absence of a palpable mass or mammographic abnormality [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H5"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>A detailed history should document the length of time the lesion has been present and any associated symptoms, including pain, nipple discharge, bleeding, burning, and pruritus. The history should also cover the patient's individual risk profile for breast cancer, including any risk factors for hereditary breast cancer. (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a> and  <a class="medical medical_review" href="/z/d/html/785.html" rel="external">"Overview of hereditary breast and ovarian cancer syndromes"</a>.)</p><p>Bilateral breast examination should be performed, focusing on associated breast abnormalities. An underlying breast malignancy is present in 85 to 88 percent of cases, and a palpable mass is present in approximately one-half. (See  <a class="medical medical_review" href="/z/d/html/804.html" rel="external">"Clinical manifestations, differential diagnosis, and clinical evaluation of a palpable breast mass", section on 'Physical examination'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes both benign etiologies (eczema, contact as well as radiation dermatitis, nipple adenoma) and malignant conditions (Bowen's disease [squamous carcinoma of the epidermis], basal cell carcinoma, superficial spreading malignant melanoma) [<a href="#rid17">17-21</a>]. </p><p>Given the differential diagnosis, a short course of topical steroids is often considered if eczema or dermatitis is suspected. However, partial healing or transient improvement in the eczematous changes may occur even in the presence of PDB. In order to avoid undue delay in definitive diagnosis, any persistent nipple abnormality beyond four to six weeks should be considered an indication for biopsy and/or breast imaging.</p><p class="headingAnchor" id="H7"><span class="h2">Skin biopsy and histology</span><span class="headingEndMark"> — </span>Nipple scrape cytology can accurately diagnose PDB [<a href="#rid22">22,23</a>], but the diagnosis is usually established by full-thickness punch or wedge biopsy of the nipple. Punch biopsy is more widely used. Wedge biopsy may contain lactiferous ducts, which may identify DCIS as the etiology of PDB. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques"</a>.)</p><p class="headingAnchor" id="H1325319276"><span class="h3">Paget cells</span><span class="headingEndMark"> — </span>The histologic hallmark of PDB is the presence of malignant, intraepithelial adenocarcinoma cells (Paget cells) occurring singly or in small groups within the epidermis of the nipple (<a class="graphic graphic_picture graphicRef81226" href="/z/d/graphic/81226.html" rel="external">picture 2</a>). The cells are often large but may be similar in size to keratinocytes. The cytoplasm is pale to clear, and nuclei are usually high-grade with prominent nucleoli. In many instances, the Paget cells retract from the surrounding keratinocytes and appear to be within a vacuole.</p><p class="headingAnchor" id="H1100684750"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>A useful immunohistochemistry (IHC) diagnostic panel for a nipple biopsy without underlying invasive cancer or DCIS may include CK7, carcinoembryonic antigen (CEA; polyclonal), p63, ER, HER2, and either SOX10, MART-1(MelanA), or HMB-45 if melanoma is also in the biopsy differential diagnosis [<a href="#rid24">24</a>].</p><p>Histologically, PDB can mimic malignant melanoma, particularly if the cells have incorporated melanin from the adjacent epidermis. The presence of cytoplasmic mucin vacuoles can aid in the diagnosis, as can special stains such as mucicarmine, which may highlight the vacuoles. IHC may also be helpful in diagnostically difficult cases (<a class="graphic graphic_table graphicRef74830" href="/z/d/graphic/74830.html" rel="external">table 1</a>) [<a href="#rid25">25</a>]. PDB can be distinguished from malignant melanoma by positive IHC for CEA (polyclonal) and negative IHC for S-100 protein; however, some cases of PDB are S-100 positive [<a href="#rid26">26</a>], and CEA may not always be expressed. MART-1, SOX10, or HMB-45 may be more useful than S-100 in confirming malignant melanoma.</p><p>Paget cells are positive for low molecular weight cytokeratins, a feature that can help distinguish PDB from squamous carcinoma of the epidermis (Bowen's disease), which typically expresses high molecular weight cytokeratins and p63 [<a href="#rid27">27,28</a>]. CK7 is probably the most useful marker, but caution must be exercised in interpreting CK7 stains in the absence of other typical histologic features of PDB. Although positive in PDB, CK7 may also be expressed in benign Toker cell hyperplasia [<a href="#rid29">29,30</a>], and some breast carcinomas may not express CK7 [<a href="#rid31">31</a>]. Toker cells in the nipple may be derived from or related to lactiferous duct epithelium, and malignant transformation of these cells may explain some cases of PDB without associated ductal carcinoma [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H2268720932"><span class="h4">Hormone receptors</span><span class="headingEndMark"> — </span>If present, estrogen and/or progesterone receptor positivity is extremely helpful. Unfortunately, approximately one-half of PDB cases do not express hormone receptors, a finding that is not surprising considering the frequent association with high-grade invasive ductal carcinomas that are also likely to be hormone receptor-negative and/or HER2 positive.</p><p>Between 84 and 91 percent of cases of PDB overexpress HER2. HER2 overexpression in PDB likely explains the worse prognosis reported for invasive breast cancer with Paget disease [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Mammography and ultrasonography</span><span class="headingEndMark"> — </span>Bilateral mammography is mandatory to identify an associated mass as well as exclude synchronous cancers or widespread calcifications that might preclude breast conservation therapy. Approximately one-half of cases of PDB have an associated mammographic abnormality [<a href="#rid15">15,34</a>]. The mammographic findings in 17 women in one study included suspicious microcalcifications, a mass, architectural distortion, nipple retraction, and asymmetric thickening of the nipple-areolar complex [<a href="#rid15">15</a>]. In seven cases, the mammographic abnormalities were located distant from the nipple-areolar complex.</p><p>As noted above, while women with a negative mammogram in the setting of PDB appear to have a low likelihood of underlying invasive breast cancer (particularly in the absence of a palpable mass [<a href="#rid16">16,35</a>]), an occult associated intraductal carcinoma may be present and quite extensive. In the above noted series, all of the 17 women with negative mammograms had DCIS, five with extensive multicentric disease [<a href="#rid15">15</a>]. In another series, mammography failed to identify 64 percent of cases of multifocal underlying breast cancer (both in situ and invasive cancer) in women with PDB and no palpable mass [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7561.html" rel="external">"Breast imaging for cancer screening: Mammography and ultrasonography"</a>.)</p><p>Ultrasound should be used to further evaluate and guide core biopsy of any palpable mass or mass-like mammographic abnormality. Whole breast ultrasound in addition to mammography has been examined in the context of Paget disease but does not appear to increase sensitivity over mammography alone [<a href="#rid37">37-39</a>]. </p><p class="headingAnchor" id="H9"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is a sensitive imaging tool for invasive breast cancer, particularly for mammographically occult disease, and its sensitivity for detecting DCIS, particularly high-grade DCIS, is also high. MRI may be most useful for women at high risk for breast cancer. (See  <a class="medical medical_review" href="/z/d/html/14219.html" rel="external">"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis", section on 'Magnetic resonance imaging'</a> and  <a class="medical medical_review" href="/z/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer"</a>.)</p><p>There are few data addressing the utility of breast MRI in women with PDB and a negative mammogram [<a href="#rid40">40-46</a>]. The largest series included 34 women with PDB, 32 of whom had a histologically confirmed breast cancer (7 invasive, 25 DCIS) [<a href="#rid40">40</a>]. All patients underwent preoperative mammography, while 13 had an ipsilateral breast MRI. Among the 23 women with biopsy-proven PDB and negative mammography, eight underwent MRIs that detected otherwise occult disease in four women (three DCIS, one invasive cancer), three of whom required mastectomy because of extensive disease. However, MRI did not detect three cancers (two unifocal DCIS, one invasive cancer) in the other four patients.</p><p>Thus, MRI may disclose occult cancer in some women with PDB and no findings on mammography or physical examination, potentially allowing directed treatment of the ipsilateral breast. However, a negative preoperative study cannot reliably exclude an underlying cancer.</p><p>In addition, because MRI is highly sensitive but not highly specific, MRI may reveal abnormalities that might lead to the overuse of mastectomy rather than breast-conserving therapy. Thus, if MRI is to be performed, it should only be undertaken at an institution that has the capability of performing MRI-guided biopsies, and the patient should be counseled regarding the high false positive rate of breast MRI and the possible need for additional biopsies.</p><p class="headingAnchor" id="H10"><span class="h2">Biopsy of underlying abnormalities</span><span class="headingEndMark"> — </span>In addition to nipple biopsy, any underlying masses or mammographic abnormalities must be biopsied to assist in decisions about local treatment of the breast and the need for evaluation of the axilla.</p><p class="headingAnchor" id="H11"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Two theories have been proposed to explain the pathogenesis of PDB: the epidermotropic theory, which is by far the more widely accepted, and the transformation theory.</p><p class="headingAnchor" id="H12"><span class="h2">Epidermotropic theory</span><span class="headingEndMark"> — </span>According to the prevailing epidermotropic theory, the Paget cell arises from an underlying mammary adenocarcinoma, with the neoplastic ductal epithelial cells migrating through the ductal system of the breast into the epidermis of the nipple.</p><p>In many series, immunohistochemical (IHC) staining is concordant in Paget cells and the ductal epithelial cells but discordant in Paget cells and the epidermal keratinocytes of the surrounding nipple tissue (<a class="graphic graphic_table graphicRef74830" href="/z/d/graphic/74830.html" rel="external">table 1</a>) [<a href="#rid9">9,47-52</a>].</p><p>Similarly, expression of several molecular markers is concordant in PDB and underlying parenchymal breast tumors [<a href="#rid47">47,53</a>]. Over 80 percent of PDBs have overexpression or amplification of the gene for HER2 [<a href="#rid17">17,18,53,54</a>]. In one report, all 23 cases of PDB stained with an anti-HER2 monoclonal antibody; staining was also positive in all the underlying ductal carcinomas but never in normal nipple epidermis [<a href="#rid8">8</a>]. It is hypothesized that the spread of Paget cells to the nipple epidermis from the duct system may be mediated through a motility factor that exerts its effect via the HER2 receptor (<a class="graphic graphic_figure graphicRef61409" href="/z/d/graphic/61409.html" rel="external">figure 1</a>) [<a href="#rid55">55</a>].</p><p>Taken together, these data lend support to a common genetic alteration and/or possibly a common progenitor cell for both the Paget cells and the underlying ductal carcinoma.</p><p class="headingAnchor" id="H13"><span class="h2">Transformation theory</span><span class="headingEndMark"> — </span>In contrast, the transformation theory proposes that epidermal keratinocytes within the nipple transform into malignant Paget cells and that PDB in fact represents an epidermal carcinoma in situ that is independent of any underlying ductal carcinoma [<a href="#rid19">19</a>]. George Thin proposed this theory in 1881, believing that secretions from the breast ducts damaged the epithelium, transforming normal keratinocytes into cancer cells [<a href="#rid2">2</a>].</p><p>The transformation theory was bolstered by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small percentage of cases, no parenchymal cancer can be identified in association with PDB.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When an underlying parenchymal carcinoma is present, it is often located peripheral to the nipple, suggesting two independent neoplastic processes. As an example, in one series of 80 women with breast cancer and PDB, 29 of the underlying breast tumors were located more than 2 cm from the areolar margin [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Desmosomal attachments have been identified between Paget cells and adjacent epidermal keratinocytes [<a href="#rid56">56</a>]. These authors describe a "pre-Paget cell" with an appearance intermediate between that of a keratinocyte and a Paget cell, suggesting that epidermal cells can acquire the characteristics of ductal cells as they undergo malignant transformation. Others suggest the presence of a unique precursor, the Toker cell, to explain cases of PDB with no contiguous ductal carcinoma [<a href="#rid32">32,57</a>].</p><p></p><p>The transformation theory has fallen out of favor, in part because if enough tissue sections are studied, involvement of the large (lactiferous) ducts immediately beneath the nipple can usually be demonstrated.</p><p class="headingAnchor" id="H14"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The presence of Paget disease of the breast does not change the stage of an underlying breast cancer. If an associated invasive breast cancer or ductal carcinoma in situ is not identified, Paget disease is classified as Tis (Paget) disease. (See  <a class="medical medical_review" href="/z/d/html/800.html" rel="external">"Tumor, node, metastasis (TNM) staging classification for breast cancer"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The most important aspect of presentation that influences the treatment decision is the presence or absence of an ipsilateral palpable breast mass or mammographic abnormality. The prognosis of PDB is based upon the underlying breast cancer, and treatment should be guided by the stage of the tumor and other prognostic and/or predictive factors.</p><p>Simple mastectomy has been the historic standard treatment for PDB. However, the widespread use of breast-conserving treatment (BCT) for invasive and in situ breast carcinoma has led to its use for PDB. In contrast to invasive breast cancer, treatment recommendations are limited by the lack of prospective randomized trials comparing mastectomy to BCT or comparing various BCT options in patients with PDB. Most reported series are small, and patient selection, treatment techniques, and median follow-up vary from study to study. (See  <a class="medical medical_review" href="/z/d/html/807.html" rel="external">"Breast-conserving therapy"</a> and  <a class="medical medical_review" href="/z/d/html/14981.html" rel="external">"Mastectomy"</a> and  <a class="medical medical_review" href="/z/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">PDB with a palpable mass or abnormal imaging</span><span class="headingEndMark"> — </span>When PDB is present in association with a palpable mass or defined mammographic abnormality, the associated breast cancer tends to be a more advanced stage (ie, larger size, multifocal, more frequent presence of invasive disease and axillary node positivity) than if a mass is absent [<a href="#rid10">10,16,36</a>]. The incidence of axillary metastases and survival in women who present with PDB with and without a palpable mass is shown here (<a class="graphic graphic_table graphicRef67429" href="/z/d/graphic/67429.html" rel="external">table 2</a>).</p><p>Both the nipple-areolar complex and the underlying cancer must be excised. Many patients will require a mastectomy. However, if nipple-areolar resection and wide local excision of the palpable mass or area of mammographic abnormality can be performed with an acceptable cosmetic result and negative margins, breast-conserving surgery followed by whole breast radiotherapy (RT) is an appropriate local treatment option. If the breasts are large, resection of the palpable mass and nipple-areolar complex with nipple reconstruction and elective contralateral breast reduction can be combined with definitive breast RT to achieve an adequate oncologic outcome with acceptable breast contour and symmetry.</p><p>Women with multicentric cancer or diffuse calcifications should be treated by mastectomy with axillary evaluation, for example by sentinel lymph node biopsy (SLNB). Many women with PDB and a palpable mass are not amenable to BCT because of the distance between the primary tumor and the nipple-areolar complex [<a href="#rid10">10</a>]. If resection of both the nipple-areolar complex and the palpable mass with a negative margin would result in an unacceptable cosmetic result, women may elect for simple mastectomy with or without breast reconstruction. (See  <a class="medical medical_review" href="/z/d/html/807.html" rel="external">"Breast-conserving therapy", section on 'Patient selection for BCT'</a> and  <a class="medical medical_review" href="/z/d/html/14981.html" rel="external">"Mastectomy", section on 'Indications for mastectomy'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">PDB with no palpable mass or imaging abnormality</span><span class="headingEndMark"> — </span>Despite the absence of a palpable mass or mammographic abnormality, underlying carcinoma is present in most patients with PDB [<a href="#rid36">36</a>]. The majority will have DCIS, but invasive cancer is present in one-fourth to one-third of cases [<a href="#rid3">3,5,58</a>]. Standard treatment options include mastectomy or breast-conserving therapy (resection of the nipple-areolar complex followed by whole breast irradiation) (<a class="graphic graphic_picture graphicRef75416" href="/z/d/graphic/75416.html" rel="external">picture 3</a>).</p><p>Simple mastectomy with or without breast reconstruction is an effective option [<a href="#rid4">4,59</a>]. In a series of 37 patients treated by simple mastectomy alone, the local recurrence rate was only 5 percent, with a median follow-up of 40 months [<a href="#rid4">4</a>].</p><p>Several reports describe the use of limited surgery or nipple-areolar resection followed by breast RT for treatment of PDB in women without a palpable breast mass (<a class="graphic graphic_table graphicRef80724" href="/z/d/graphic/80724.html" rel="external">table 3</a>) [<a href="#rid8">8,35,60-63</a>]. Rates of local recurrence, successful salvage, and distant disease-free survival are comparable to those seen with DCIS [<a href="#rid64">64</a>]. The following represents the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>A study of 36 patients with PDB and no underlying palpable mass or mammographic abnormality who underwent complete or partial resection of the nipple-areolar complex followed by RT demonstrated a local recurrence rate of 11 percent at a median follow-up of 112 months [<a href="#rid8">8</a>]. Of the 22 patients undergoing complete nipple-areolar resection followed by whole breast RT with a boost (total dose 61.5 Gy), three (14 percent) developed a local recurrence. In contrast, two of six women (33 percent) treated with the same dose of RT but only a partial nipple-areolar resection recurred locally, one with distant metastases. All four women with an isolated local recurrence were treated successfully with salvage mastectomy and remained disease free at the time of last follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The European Organization for Research and Treatment of Cancer (EORTC) conducted a prospective study of BCT for PDB [<a href="#rid35">35</a>]. This study excluded women with invasive cancer. Of the 61 women enrolled in the study with histologically proven PDB, 97 percent had no associated palpable mass, and 84 percent had a normal mammogram. Associated DCIS was present in 93 percent, and the remainder had no underlying parenchymal carcinoma. Treatment consisted of complete nipple-areolar resection followed by whole breast RT (median dose 50 Gy). There were four local recurrences (6.5 percent), with a median follow-up of 6.4 years. Three recurrences were invasive, and one was DCIS; one patient with an invasive recurrence subsequently died of metastatic disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several subsequent retrospective studies comparing BCT with mastectomy showed that the type of surgery did not demonstrate a difference in outcomes (eg, survival, recurrence) of patients with PDB [<a href="#rid13">13,65-68</a>]. The long-term outcomes in PDB are primarily determined by the associated invasive cancer or DCIS. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p>Taken together, these data suggest that complete resection of the nipple-areolar complex with central lumpectomy, as clinically appropriate, followed by whole breast RT is a reasonable alternative to mastectomy for women with PDB and no palpable mass or mammographic abnormality provided good cosmetic outcome and negative margins can be achieved. A variety of techniques can be used to reconstruct the nipple-areolar complex, and cosmesis has been assessed as good to excellent in the majority of patients so treated. (See  <a class="medical medical_review" href="/z/d/html/14976.html" rel="external">"Oncoplastic breast surgery"</a>.)</p><p>In some cases of PDB without a mass or mammographic abnormality, the pathologic evaluation of the nipple/areolar complex may detect secondary invasion into the subjacent dermis. In one series of six cases with secondary dermal invasion, there was no underlying breast carcinoma in one case, DCIS only in three cases, DCIS with microinvasion in one case, and invasive carcinoma in one case. Treatment was determined by the underlying disease. One patient died of unrelated causes, and the remainder were alive at last follow-up [<a href="#rid69">69</a>]. In a second series of seven patients, five patients had microinvasive (&lt;1 mm) dermal foci, and the two remaining patients had 2 and 3 mm foci of dermal invasion. Two patients at high risk for breast cancer underwent mastectomy, and the average-risk patients were treated with breast-conserving therapy and RT; no recurrences were reported (median follow-up 20 months [range 4 to 66 months]) [<a href="#rid70">70</a>]. While there is limited information available on patients with secondary dermal invasion, this finding does not indicate more adverse outcomes and should be distinguished from locally advanced breast cancer with skin involvement (T4b).</p><p class="headingAnchor" id="H18"><span class="h2">Management of the axilla</span><span class="headingEndMark"> — </span>The risk of axillary metastases in series of patients with PDB is higher in women with invasive cancer and a palpable mass (<a class="graphic graphic_table graphicRef67429" href="/z/d/graphic/67429.html" rel="external">table 2</a>) [<a href="#rid9">9,10,58,59,71,72</a>].</p><p>Evaluation and treatment of the axilla in PDB are the same as for any breast cancer and depend on the underlying cancer (see  <a class="medical medical_review" href="/z/d/html/813.html" rel="external">"Overview of management of the regional lymph nodes in breast cancer"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with DCIS do not require axillary investigation unless the disease is extensive enough to merit mastectomy. If mastectomy is planned, sentinel lymph node (SLN) biopsy is often (and appropriately) performed preemptively in order to avoid complete axillary lymph node dissection in cases with an invasive component identified at final pathology. (See  <a class="medical medical_review" href="/z/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If invasive disease has been identified, patients with clinically node-negative disease should undergo SLN biopsy at the time of wide excision. An SLN can be successfully identified in 97 percent of patients with PDB [<a href="#rid72">72</a>]. Management of a positive SLN is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a clinically positive or suspicious axilla should undergo an initial ultrasound-guided fine needle aspiration (FNA) or core needle biopsy of the palpable axillary nodes; if disease is confirmed histologically, full axillary lymph node dissection (ALND) is recommended. In contrast, if the FNA or core biopsy is negative, SLB biopsy should be performed. SLN biopsy after neoadjuvant chemotherapy may be an option for some highly selected patients with clinically positive axillary nodes. (See  <a class="medical medical_review" href="/z/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Positive axilla prior to treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with pure PDB without an associated mass and a clinically negative axilla, there is some controversy as to the need for axillary evaluation when breast conservation is planned. Given the high incidence of DCIS alone in these patients, SLN biopsy may not be necessary and can be considered as a second operation if invasive disease is discovered [<a href="#rid72">72</a>]. In a series of 19 patients with PDB only, an invasive component was found in 27 percent and positive SLNs in 11 percent [<a href="#rid58">58</a>]. Based on these numbers, some consider the likelihood of invasive disease high enough to recommend an SLN biopsy in this situation routinely. (See  <a class="medical medical_review" href="/z/d/html/810.html" rel="external">"Overview of sentinel lymph node biopsy in breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Alternative approaches</span><span class="headingEndMark"> — </span>Mastectomy and BCT (surgery plus whole breast RT) represent standard approaches to treatment of PDB without an underlying mass or mammographic abnormality. Less aggressive approaches have been examined, including ipsilateral breast RT following only a diagnostic nipple biopsy [<a href="#rid60">60-63</a>] and breast-conserving surgery without RT (<a class="graphic graphic_table graphicRef60782" href="/z/d/graphic/60782.html" rel="external">table 4</a>) [<a href="#rid4">4,59,73,74</a>]; however, only small numbers of patients have been studied, and reported results are variable. Thus, neither of these approaches can be considered a standard treatment option for most patients with PDB in the absence of an underlying mass.</p><p>Few areas in breast cancer treatment are as contentious as the obligate need for RT as a component of BCT in women with DCIS. Proponents of RT for all women with DCIS argue that local recurrence rates are substantially higher when RT is withheld and that one-half of all local recurrences are invasive. Others contend that RT represents overly aggressive therapy for many women with DCIS and that by weighing factors of prognostic importance (ie, grade, size, age, and distance to margins), a sizable subset can be identified who have excellent recurrence-free survival with excision alone. These issues are all discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Use of tamoxifen</span><span class="headingEndMark"> — </span>There are no data addressing the efficacy of endocrine therapy, including <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, in reducing the risk for local recurrence in patients with PDB without an underlying invasive carcinoma or DCIS who are treated with breast-conserving therapy. Recommendations regarding endocrine therapy (tamoxifen or aromatase inhibitors) as well as other forms of adjuvant systemic therapy such as chemotherapy and <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> should be based solely upon the characteristics of any associated invasive carcinoma or DCIS. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/14220.html" rel="external">"Ductal carcinoma in situ: Treatment and prognosis", section on 'Systemic treatment'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of PDB is dependent upon the presence of an underlying invasive ductal carcinoma or axillary node metastases. Tumor stage is a better indicator of prognosis than the presence of Paget disease per se.</p><p>As noted above, PDB presenting with a palpable mass is usually associated with more advanced disease than cases without a palpable mass; because of this, five-year survival rates are also lower (<a class="graphic graphic_table graphicRef57584" href="/z/d/graphic/57584.html" rel="external">table 5</a>) [<a href="#rid9">9,10,59,71</a>]. In general, for women with PDB associated with a palpable mass, five-year survival ranges from 20 to 60 percent, while for women without a palpable mass, survival ranges from 75 to 100 percent [<a href="#rid10">10,19,59,71</a>].</p><p>For patients with a palpable mass and invasive ductal carcinoma, five-year cause-specific survival ranges from 37 to 43 percent, while in patients without a mass and with ductal carcinoma in situ (DCIS) only, the five-year cause-specific survival is 90 to 100 percent [<a href="#rid3">3-5,8</a>].</p><p class="headingAnchor" id="H3987642405"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Paget disease of the breast (PDB) is clinically characterized by a persistent scaling, eczematous, or ulcerated lesion involving the nipple-areolar complex. The pathologic hallmark and defining feature is the presence of malignant, intraepithelial adenocarcinoma cells (Paget cells) within the epidermis of the nipple. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – PDB is associated with an underlying breast cancer (in situ [ductal carcinoma in situ; DCIS] and/or invasive) in 85 to 88 percent of cases, often without an associated breast mass or mammographic abnormality. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PDB can usually be established by punch or full-thickness wedge biopsy of the nipple. Biopsy of any underlying mass or mammographic abnormality is required to assist in decisions about local treatment of the breast and the need for evaluation of the axilla. (See <a class="local">'Diagnostic workup'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnostic workup of all patients with PDB should include careful physical examination of both breasts and mammography. Breast magnetic resonance imaging (MRI) may be considered in a patient with a negative physical examination and mammogram. All mammographically occult lesions that are identified by MRI do not represent cancer, and confirmatory biopsy is needed. Thus, MRI should only be obtained at institutions with the capability of performing MRI-guided biopsy. (See <a class="local">'Diagnostic workup'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Women who have a palpable mass in association with PDB are more likely to harbor invasive breast cancer than those with no palpable mass, and they are also more likely to have involved axillary lymph nodes. (See <a class="local">'PDB with a palpable mass or abnormal imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Women with PDB and no palpable underlying mass or radiographic abnormality have a lower likelihood of harboring invasive breast cancer; the majority have underlying DCIS. (See <a class="local">'PDB with no palpable mass or imaging abnormality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The prognosis of PDB is based upon the underlying breast cancer, and treatment should be guided by the stage of the tumor and other prognostic and/or predictive factors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If an invasive breast cancer is identified, it should be treated like any other invasive breast cancer, with consideration of adjuvant systemic therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation and treatment of the axilla in PDB are the same as for any breast cancer and depend on the underlying cancer identified and the planned surgical procedure (breast-conserving surgery or total mastectomy). (See <a class="local">'Management of the axilla'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Both mastectomy and breast-conserving surgery followed by whole breast radiotherapy (RT) are acceptable treatment options. Breast-conserving surgery and RT should only be performed when a nipple-areolar resection and wide local excision of the underlying cancer can be performed with an acceptable cosmetic result and negative margins. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recommendations regarding the use of endocrine therapy as well as other forms of adjuvant systemic therapy in patients with PDB should be based upon the characteristics of the underlying carcinoma. There are no data to support the use of endocrine therapy in women with PDB without an associated invasive cancer or DCIS. (See <a class="local">'Use of tamoxifen'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Paget J. On disease of the mammary areola preceding cancer of the mammary gland. Bartholomew's Hosp Rep 1874; 10:87.</a></li><li><a class="nounderline abstract_t">Thin G. On the connection between disease of the nipple and areola and tumors of the breast. Trans Pathol Soc Lond 1881; 32:218.</a></li><li><a class="nounderline abstract_t">Ashikari R, Park K, Huvos AG, Urban JA. Paget's disease of the breast. Cancer 1970; 26:680.</a></li><li><a class="nounderline abstract_t">Dixon AR, Galea MH, Ellis IO, et al. Paget's disease of the nipple. Br J Surg 1991; 78:722.</a></li><li><a class="nounderline abstract_t">Nance FC, DeLoach DH, Welsh RA, Becker WF. Paget's disease of the breast. Ann Surg 1970; 171:864.</a></li><li><a class="nounderline abstract_t">Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75:257.</a></li><li><a class="nounderline abstract_t">Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.</a></li><li><a class="nounderline abstract_t">Marshall JK, Griffith KA, Haffty BG, et al. Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. Cancer 2003; 97:2142.</a></li><li><a class="nounderline abstract_t">Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 1986; 8:139.</a></li><li><a class="nounderline abstract_t">Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd. Paget's disease of the breast: a 33-year experience. J Am Coll Surg 1998; 187:171.</a></li><li><a class="nounderline abstract_t">Caliskan M, Gatti G, Sosnovskikh I, et al. Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2008; 112:513.</a></li><li><a class="nounderline abstract_t">Lagios MD, Gates EA, Westdahl PR, et al. A guide to the frequency of nipple involvement in breast cancer. A study of 149 consecutive mastectomies using a serial subgross and correlated radiographic technique. Am J Surg 1979; 138:135.</a></li><li><a class="nounderline abstract_t">Chen CY, Sun LM, Anderson BO. Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer 2006; 107:1448.</a></li><li><a class="nounderline abstract_t">Franceschini G, Masetti R, D'Ugo D, et al. Synchronous bilateral Paget's disease of the nipple associated with bilateral breast carcinoma. Breast J 2005; 11:355.</a></li><li><a class="nounderline abstract_t">Ikeda DM, Helvie MA, Frank TS, et al. Paget disease of the nipple: radiologic-pathologic correlation. Radiology 1993; 189:89.</a></li><li><a class="nounderline abstract_t">Zakaria S, Pantvaidya G, Ghosh K, Degnim AC. Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat 2007; 102:137.</a></li><li><a class="nounderline abstract_t">Vielh P, Validire P, Kheirallah S, et al. Paget's disease of the nipple without clinically and radiologically detectable breast tumor. Histochemical and immunohistochemical study of 44 cases. Pathol Res Pract 1993; 189:150.</a></li><li><a class="nounderline abstract_t">Lammie GA, Barnes DM, Millis RR, Gullick WJ. An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Histopathology 1989; 15:505.</a></li><li><a class="nounderline abstract_t">Jamali FR, Ricci A Jr, Deckers PJ. Paget's disease of the nipple-areola complex. Surg Clin North Am 1996; 76:365.</a></li><li><a class="nounderline abstract_t">Miller L, Tyler W, Maroon M, Miller OF 3rd. Erosive adenomatosis of the nipple: a benign imitator of malignant breast disease. Cutis 1997; 59:91.</a></li><li><a class="nounderline abstract_t">Kobayashi TK, Ueda M, Nishino T, et al. Scrape cytology of pemphigus vulgaris of the nipple, a mimicker of Paget's disease. Diagn Cytopathol 1997; 16:156.</a></li><li><a class="nounderline abstract_t">Gupta RK, Simpson J, Dowle C. The role of cytology in the diagnosis of Paget's disease of the nipple. Pathology 1996; 28:248.</a></li><li><a class="nounderline abstract_t">Lucarotti ME, Dunn JM, Webb AJ. Scrape cytology in the diagnosis of Paget's disease of the breast. Cytopathology 1994; 5:301.</a></li><li><a class="nounderline abstract_t">Zhao L, Yang X, Khan A, Kandil D. Diagnostic role of immunohistochemistry in the evaluation of breast pathology specimens. Arch Pathol Lab Med 2014; 138:16.</a></li><li><a class="nounderline abstract_t">Compton LA, Murphy GF, Lian CG. Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update. Dermatopathology (Basel) 2015; 2:15.</a></li><li><a class="nounderline abstract_t">Gillett CE, Bobrow LG, Millis RR. S100 protein in human mammary tissue--immunoreactivity in breast carcinoma, including Paget's disease of the nipple, and value as a marker of myoepithelial cells. J Pathol 1990; 160:19.</a></li><li><a class="nounderline abstract_t">Barrutia L, Martínez-García G, Santamarina-Albertos A, et al. Differentiating pagetoid Bowen disease from Paget disease on the nipple-areola complex: Two unique, challenging cases. J Cutan Pathol 2021; 48:1416.</a></li><li><a class="nounderline abstract_t">Zhao Z, Tay TKY, Agrawal R, et al. Intraepidermal malignancy in breast skin: A tale of two tumours. Human Pathology: Case Reports 2018; 14:33.</a></li><li><a class="nounderline abstract_t">Yao DX, Hoda SA, Chiu A, et al. Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent interepithelial extension of lactiferous duct cells. Histopathology 2002; 40:230.</a></li><li><a class="nounderline abstract_t">Lundquist K, Kohler S, Rouse RV. Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells. Am J Surg Pathol 1999; 23:212.</a></li><li><a class="nounderline abstract_t">Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000; 13:962.</a></li><li><a class="nounderline abstract_t">van der Putte SC, Toonstra J, Hennipman A. Mammary Paget's disease confined to the areola and associated with multifocal Toker cell hyperplasia. Am J Dermatopathol 1995; 17:487.</a></li><li><a class="nounderline abstract_t">Kothari AS, Beechey-Newman N, Hamed H, et al. Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer 2002; 95:1.</a></li><li><a class="nounderline abstract_t">Ceccherini AF, Evans AJ, Pinder SE, et al. Is ipsilateral mammography worthwhile in Paget's disease of the breast? Clin Radiol 1996; 51:35.</a></li><li><a class="nounderline abstract_t">Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2001; 91:472.</a></li><li><a class="nounderline abstract_t">Yim JH, Wick MR, Philpott GW, et al. Underlying pathology in mammary Paget's disease. Ann Surg Oncol 1997; 4:287.</a></li><li><a class="nounderline abstract_t">Muttarak M, Siriya B, Kongmebhol P, et al. Paget's disease of the breast: clinical, imaging and pathologic findings: a review of 16 patients. Biomed Imaging Interv J 2011; 7:e16.</a></li><li><a class="nounderline abstract_t">Günhan-Bilgen I, Oktay A. Paget's disease of the breast: clinical, mammographic, sonographic and pathologic findings in 52 cases. Eur J Radiol 2006; 60:256.</a></li><li><a class="nounderline abstract_t">Kalima T, Sipponen J, Kivilaakso E, Sipponen P. Decreased prevalence of gallstones in gastric cancer. Am J Surg 1982; 144:531.</a></li><li><a class="nounderline abstract_t">Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple. J Am Coll Surg 2008; 206:316.</a></li><li><a class="nounderline abstract_t">Echevarria JJ, Lopez-Ruiz JA, Martin D, et al. Usefulness of MRI in detecting occult breast cancer associated with Paget's disease of the nipple-areolar complex. Br J Radiol 2004; 77:1036.</a></li><li><a class="nounderline abstract_t">Capobianco G, Spaliviero B, Dessole S, et al. Paget's disease of the nipple diagnosed by MRI. Arch Gynecol Obstet 2006; 274:316.</a></li><li><a class="nounderline abstract_t">Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005; 40:363.</a></li><li><a class="nounderline abstract_t">Amano G, Yajima M, Moroboshi Y, et al. MRI accurately depicts underlying DCIS in a patient with Paget's disease of the breast without palpable mass and mammography findings. Jpn J Clin Oncol 2005; 35:149.</a></li><li><a class="nounderline abstract_t">Kim HS, Seok JH, Cha ES, et al. Significance of nipple enhancement of Paget's disease in contrast enhanced breast MRI. Arch Gynecol Obstet 2010; 282:157.</a></li><li><a class="nounderline abstract_t">Corsi F, Sartani A, Galli D, et al. Usefulness of Preoperative Diagnosis with Magnetic Resonance Imaging for Conservative Surgery in Paget's Disease of the Breast. Breast Care (Basel) 2010; 5:26.</a></li><li><a class="nounderline abstract_t">Fu W, Lobocki CA, Silberberg BK, et al. Molecular markers in Paget disease of the breast. J Surg Oncol 2001; 77:171.</a></li><li><a class="nounderline abstract_t">NEUBECKER RD, BRADSHAW RP. Mucin, melanin, and glycogen in Paget's disease of the breast. Am J Clin Pathol 1961; 36:49.</a></li><li><a class="nounderline abstract_t">Bussolati G, Pich A. Mammary and extramammary Paget's disease. An immunocytochemical study. Am J Pathol 1975; 80:117.</a></li><li><a class="nounderline abstract_t">Kirkham N, Berry N, Jones DB, Taylor-Papadimitriou J. Paget's disease of the nipple. Immunohistochemical localization of milk fat globule membrane antigens. Cancer 1985; 55:1510.</a></li><li><a class="nounderline abstract_t">Nadji M, Morales AR, Girtanner RE, et al. Paget's disease of the skin. A unifying concept of histogenesis. Cancer 1982; 50:2203.</a></li><li><a class="nounderline abstract_t">Vanstapel MJ, Gatter KC, De Wolf-Peeters C, et al. Immunohistochemical study of mammary and extra-mammary Paget's disease. Histopathology 1984; 8:1013.</a></li><li><a class="nounderline abstract_t">Meissner K, Rivière A, Haupt G, Löning T. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. Am J Pathol 1990; 137:1305.</a></li><li><a class="nounderline abstract_t">Anderson JM, Ariga R, Govil H, et al. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl Immunohistochem Mol Morphol 2003; 11:120.</a></li><li><a class="nounderline abstract_t">Schelfhout VR, Coene ED, Delaey B, et al. Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family. J Natl Cancer Inst 2000; 92:622.</a></li><li><a class="nounderline abstract_t">Sagebiel RW. Ultrastructural observations on epidermal cells in Paget's disease of the breast. Am J Pathol 1969; 57:49.</a></li><li><a class="nounderline abstract_t">Decaussin M, Laville M, Mathevet P, Frappart L. Paget's disease versus Toker cell hyperplasia in a supernumerary nipple. Virchows Arch 1998; 432:289.</a></li><li><a class="nounderline abstract_t">Sukumvanich P, Bentrem DJ, Cody HS 3rd, et al. The role of sentinel lymph node biopsy in Paget's disease of the breast. Ann Surg Oncol 2007; 14:1020.</a></li><li><a class="nounderline abstract_t">Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981; 48:825.</a></li><li><a class="nounderline abstract_t">Fourquet A, Campana F, Vielh P, et al. Paget's disease of the nipple without detectable breast tumor: conservative management with radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:1463.</a></li><li><a class="nounderline abstract_t">Bulens P, Vanuytsel L, Rijnders A, van der Schueren E. Breast conserving treatment of Paget's disease. Radiother Oncol 1990; 17:305.</a></li><li><a class="nounderline abstract_t">Stockdale AD, Brierley JD, White WF, et al. Radiotherapy for Paget's disease of the nipple: a conservative alternative. Lancet 1989; 2:664.</a></li><li><a class="nounderline abstract_t">Rissanen PM, Holsti P. Paget's disease of the breast: the influence of the presence or absence of an underlying palpable tumor on the prognosis and on the choice of treatment. Oncology 1969; 23:209.</a></li><li><a class="nounderline abstract_t">Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996; 14:754.</a></li><li><a class="nounderline abstract_t">Helme S, Harvey K, Agrawal A. Breast-conserving surgery in patients with Paget's disease. Br J Surg 2015; 102:1167.</a></li><li><a class="nounderline abstract_t">Kawase K, Dimaio DJ, Tucker SL, et al. Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol 2005; 12:391.</a></li><li><a class="nounderline abstract_t">Singh A, Sutton RJ, Baker CB, Sacks NP. Is mastectomy overtreatment for Paget's disease of the nipple? Breast 1999; 8:191.</a></li><li><a class="nounderline abstract_t">Dalberg K, Hellborg H, Wärnberg F. Paget's disease of the nipple in a population based cohort. Breast Cancer Res Treat 2008; 111:313.</a></li><li><a class="nounderline abstract_t">Duan X, Sneige N, Gullett AE, et al. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol 2012; 36:1353.</a></li><li><a class="nounderline abstract_t">Sanders MA, Dominici L, Denison C, et al. Paget disease of the breast with invasion from nipple skin into the dermis: an unusual type of skin invasion not associated with an adverse outcome. Arch Pathol Lab Med 2013; 137:72.</a></li><li><a class="nounderline abstract_t">Eusebio RB, Deckers PJ. Paget's disease of the nipple-areola complex: A plea for conservatism. Contemp Surg 1992; 40:13.</a></li><li><a class="nounderline abstract_t">Laronga C, Hasson D, Hoover S, et al. Paget's disease in the era of sentinel lymph node biopsy. Am J Surg 2006; 192:481.</a></li><li><a class="nounderline abstract_t">Lagios MD, Westdahl PR, Rose MR, Concannon S. Paget's disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma. Cancer 1984; 54:545.</a></li><li><a class="nounderline abstract_t">Polgár C, Orosz Z, Kovács T, Fodor J. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2002; 94:1904.</a></li></ol></div><div id="topicVersionRevision">Topic 814 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : On disease of the mammary areola preceding cancer of the mammary gland</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : On the connection between disease of the nipple and areola and tumors of the breast</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4318756" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1648987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Paget's disease of the nipple.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4316089" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001000" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685461" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712465" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2434164" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704964" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paget's disease of the breast: a 33-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18240020" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/223463" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A guide to the frequency of nipple involvement in breast cancer. A study of 149 consecutive mastectomies using a serial subgross and correlated radiographic technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16933329" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174159" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Synchronous bilateral Paget's disease of the nipple associated with bilateral breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8396786" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Paget disease of the nipple: radiologic-pathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17028984" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Paget's disease of the breast: accuracy of preoperative assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8391688" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Paget's disease of the nipple without clinically and radiologically detectable breast tumor. Histochemical and immunohistochemical study of 44 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574705" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Paget's disease of the nipple-areola complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040979" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erosive adenomatosis of the nipple: a benign imitator of malignant breast disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9067110" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Scrape cytology of pemphigus vulgaris of the nipple, a mimicker of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912355" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The role of cytology in the diagnosis of Paget's disease of the nipple.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7529588" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Scrape cytology in the diagnosis of Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24377808" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnostic role of immunohistochemistry in the evaluation of breast pathology specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27047932" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2156036" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : S100 protein in human mammary tissue--immunoreactivity in breast carcinoma, including Paget's disease of the nipple, and value as a marker of myoepithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34164837" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differentiating pagetoid Bowen disease from Paget disease on the nipple-areola complex: Two unique, challenging cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intraepidermal malignancy in breast skin: A tale of two tumours</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895488" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intraepidermal cytokeratin 7 immunoreactive cells in the non-neoplastic nipple may represent interepithelial extension of lactiferous duct cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9989849" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intraepidermal cytokeratin 7 expression is not restricted to Paget cells but is also seen in Toker cells and Merkel cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007036" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8599455" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mammary Paget's disease confined to the areola and associated with multifocal Toker cell hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115309" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paget disease of the nipple: a multifocal manifestation of higher-risk disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549045" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Is ipsilateral mammography worthwhile in Paget's disease of the breast?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11169928" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9181226" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Underlying pathology in mammary Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22287988" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paget's disease of the breast: clinical, imaging and pathologic findings: a review of 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887314" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Paget's disease of the breast: clinical, mammographic, sonographic and pathologic findings in 52 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7137462" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Decreased prevalence of gallstones in gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222386" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : MRI identifies otherwise occult disease in select patients with Paget disease of the nipple.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569646" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Usefulness of MRI in detecting occult breast cancer associated with Paget's disease of the nipple-areolar complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16622685" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Paget's disease of the nipple diagnosed by MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15905723" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741305" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : MRI accurately depicts underlying DCIS in a patient with Paget's disease of the breast without palpable mass and mammography findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19838723" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Significance of nipple enhancement of Paget's disease in contrast enhanced breast MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22619638" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Usefulness of Preoperative Diagnosis with Magnetic Resonance Imaging for Conservative Surgery in Paget's Disease of the Breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11455553" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Molecular markers in Paget disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13728485" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mucin, melanin, and glycogen in Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/168778" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mammary and extramammary Paget's disease. An immunocytochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983857" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Paget's disease of the nipple. Immunohistochemical localization of milk fat globule membrane antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6290027" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Paget's disease of the skin. A unifying concept of histogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6098546" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Immunohistochemical study of mammary and extra-mammary Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1701961" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12777994" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10772679" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4310578" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Ultrastructural observations on epidermal cells in Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532009" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Paget's disease versus Toker cell hyperplasia in a supernumerary nipple.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195914" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The role of sentinel lymph node biopsy in Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6265059" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Pathogenesis and treatment of Paget's disease of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3040645" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Paget's disease of the nipple without detectable breast tumor: conservative management with radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2160679" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Breast conserving treatment of Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2570909" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Radiotherapy for Paget's disease of the nipple: a conservative alternative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4306622" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Paget's disease of the breast: the influence of the presence or absence of an underlying palpable tumor on the prognosis and on the choice of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622021" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175231" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Breast-conserving surgery in patients with Paget's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15915373" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paget's disease of the breast: there is a role for breast-conserving therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14731439" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Is mastectomy overtreatment for Paget's disease of the nipple?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952590" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Paget's disease of the nipple in a population based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895267" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23276177" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Paget disease of the breast with invasion from nipple skin into the dermis: an unusual type of skin invasion not associated with an adverse outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Paget's disease of the nipple-areola complex: A plea for conservatism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16978954" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Paget's disease in the era of sentinel lymph node biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6329506" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Paget's disease of the nipple. Alternative management in cases without or with minimal extent of underlying breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920556" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
